Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Acute toxicity: via oral route

The harmonized LD50 cut-off value of CJ306 was 5000 mg/kg or Unclassified (OECD TG423).

Acute toxicity: via dermal route

The LD50 of CJ306 was greater than 2000 mg/kg bw (OECD TG402).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
From December 21, 2015 to December 15, 2016
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
GLP compliance:
yes
Test type:
acute toxic class method
Species:
rat
Strain:
Sprague-Dawley
Sex:
female
Details on test animals or test system and environmental conditions:
- Source: BioLASCO Taiwan Co., Ltd (Taipei, Taiwan)
- Age at study initiation: 8-10 week old
- Housing: one or two animals per cage
- Diet: ad libitum
- Water: ad libitum
- Temperature (°C): 20.2-22.1 °C
- Humidity (%): 41.0-68.4%
- Photoperiod (hrs dark / hrs light): 12-hrs dark / 12-hrs light cycle
Route of administration:
oral: gavage
Vehicle:
water
Remarks:
water for injection
Doses:
Dose Step 1: 2000 mg/kg
Dose Step 2: 2000 mg/kg
No. of animals per sex per dose:
Dose Step 1: three female
Dose Step 2: three female
Sex:
female
Dose descriptor:
LD50 cut-off
Effect level:
5 000 mg/kg bw
Based on:
test mat.

Respectively, the mortalities andclinical observations in Dose Step 1 and 2 as below:

In Dose Step 1

No mortality occurred within the first three days post-dose.All dose animals tolerated the dose well and survived to termination on Day 15.Pink stained hair over the ano-genital area, forelimbs, forepaws, hindpaws, and/or mouth was noted on Day 1 through Day 3. On Day 6 and Day7, one animal (ID No. 0021) was also noted that pink stained hair over back. One animal (ID No. 0020) wasobservedthe hair loss of the forelimbs on Day 6 and the signs persisted to study completion.

In Dose Step 2

All dose animals tolerated the dose well and survived to termination on Day 15.Study animals were seen to excrete red colored feces for first three days post dose and two study animals (ID No. 0023 and 0024) were seen to excrete watery consistency feces within the first two days post dose.No abnormal excretion was reported after Day 3. Pink stained hair over the ano-genital area, forelimbs, forepaws, hindpaws, and/or mouth was noted on Day 1 through Day 3. One animal (ID No. 0022) was observed the hair loss of the forelimbs after dosing and the signs persisted to study completion. There were no records of animal observations on Day 12 and Day 13.

 

In Dose Step 1 and 2, body weights increased throughout the study period andgross examination at termination revealed no remarkable changes or lesions in all dose animals.

Interpretation of results:
GHS criteria not met
Conclusions:
According to OECD 423 test method a, the harmonized LD50 cut-off value of CJ306 was 5000 mg/kg. Therefore, CJ306 was Category 5 or Unclassified based on GHS criteria.
Executive summary:

This test using the procedures outlined in the QPS Taiwan Study Plan for T65315004-GN which is based on the SOP for the OECD 423 and OECD 423 (OECD, 2002).A total of 6 female Sprague-Dawley rats were orally dosed with CJ306 in two dose steps of three animals each, at 2000 mg/kg b.w. for both Dose Step 1 and Dose Step 2.All animals in the two dose steps tolerated the test article well with increasing body weights and no mortality or moribundity reported.The only remarkable clinical signs observed were excretion of red feces within the first three days post dose in Dose Step 2.Instances of forelimb hair loss were also noted. In absence of mortality, moribund state, or other significant clinical and gross signs of toxicity, these results place CJ306 in the GHS Category 5 or Unclassified, with harmonized LD50 cut-off value at 5,000 mg/kg or Unclassified.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
5 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available
Quality of whole database:
Limited exposure evisaged.

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
From January 05, 2017 to May 03, 2017
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
GLP compliance:
yes
Test type:
standard acute method
Limit test:
yes
Species:
rat
Strain:
Wistar
Remarks:
Crl:WI
Sex:
male/female
Details on test animals or test system and environmental conditions:
- Source: Charles River Laboratories, Research Models and Services
- Females (if applicable) nulliparous and non-pregnant: yes
- Weight at study initiation: 233-258g
- Housing: Individual caging
- Acclimation period: 6 Days
- Temperature (°C): 19.4-25.6 °C
- Humidity (%): 26-46%
- Photoperiod: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Type of coverage:
semiocclusive
Duration of exposure:
24 hours
Doses:
2000 mg/kg bw
No. of animals per sex per dose:
Five
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
No mortality.
Clinical signs:
There were no systemic clinical signs noted in any animal throughout the study. But reddish discoloration (on the basis of visual inspection) by the test item was observed on the treated area from Days 1 up to Day 3 after the application.
Body weight:
There were no treatment related effects on body weight or body weight gain during the observation period.
Gross pathology:
There was no evidence of any gross macroscopic changes.
Interpretation of results:
Category 5 based on GHS criteria
Conclusions:
According to OECD 402 test method, the LD50 of CJ306 was greater than 2000 mg/kg body weight. Therefore, CJ306 was Category 5 or Unclassified based on GHS criteria.
Executive summary:

This test using the procedures outlined in the CiToxLAB Study Plan for16/378-002Pand OECD 402 (OECD, 1987). A limit test was carried out at 2000 mg/kg body weight in both sexes (5 rats/sex) of Crl:WI Wistar rats. CJ306 did not cause mortality and no evidence of any gross macroscopic changes in necropsy. There were no systemic clinical signs noted in any animal throughout the study. No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period. The body weight loss was not observed in any other animals. Therefore, LD50 of CJ 306 was greater than 2,000 mg/kg bw.

 

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

Acute toxicity: via oral route

A total of 6 female Sprague-Dawley rats were orally dosed with CJ306 in two dose steps of three animals each, at 2000 mg/kg b.w. for both Dose Step 1 and Dose Step 2.All animals in the two dose steps tolerated the test article well with increasing body weights and no mortality or moribundity reported.The only remarkable clinical signs observed were excretion of red feces within the first three days post dose in Dose Step 2. Instances of forelimb hair loss were also noted. In absence of mortality, moribund state, or other significant clinical and gross signs of toxicity, these results place CJ306 in the GHS Category 5 or Unclassified, with harmonized LD50 cut-off value at 5,000 mg/kg or Unclassified.

Acute toxicity: via dermal route

A limit test was carried out at 2000 mg/kg body weight in both sexes (5 rats/sex) of Crl:WI Wistar rats.CJ306 did not cause mortality and no evidence of any gross macroscopic changes in necropsy. There were no systemic clinical signs noted in any animal throughout the study. No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period. The body weight loss was not observed in any other animals. Therefore, LD50 of CJ 306 was greater than 2,000 mg/kg bw.

Justification for classification or non-classification